Search Results - mechanism-of-action+biomarker

51 Results Sort By:
Treatment of fibrosis-associated pathologies through downstream TGF-β pathway inhibition
Value PropositionInhibits downstream signaling pathway of TGF-β signaling, reducing pleiotropic and off-target effects.Selectively targets tissue specific calpains, increasing efficacy as compared to current TGF-β signaling pathway inhibitory methods.Applicable to several disease models with specific focus on epithelial-to-mesenchymal transition pathologies....
Published: 5/9/2024   |   Inventor(s): David Kim, Harry Dietz
Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, Fibrosis Disorders, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Fibrosis, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities
DNA methylation markers for metastatic prostate cancer
Value Proposition:·        Detection of methylation patterns that are linked to prostate cancer development in an individual.·        Enable development of a personalized treatment plan for individuals with aggressive prostate cancer.·        Simultaneous determination of gene methylation and copy number. Technology DescriptionResearchers at Johns Hopkins...
Published: 5/9/2024   |   Inventor(s): George Bova, William Nelson, Martin Aryee, William Isaacs, Srinivasan Yegnasubramanian
Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, Epigenetic, In Vitro Diagnostics, Mechanism-of-action Biomarker, Methylation, Prostate Cancer, Therapeutic Matter, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer
Large-scale Epigenomic Reprogramming Links Anabolic Glucose Metabolism to Distant Metastasis during the Evolution of Pancreatic Cancer Progression
Unmet NeedPancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer death in the western world by 2020.  Subclonal populations that emerge and drive metastatic progression of the disease are associated with high mortality rates among patients.  Blocking the tumorigenic potential of metastatic sites is key to improving...
Published: 5/9/2024   |   Inventor(s): Andrew Feinberg, Xin Li, Christine Iacobuzio-Donahue, Oliver McDonald
Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Pancreatic Cancer
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer
Novel HIV Antiviral Proteins and Their Uses in Therapeutic Methods
Unmet Need: HIV infection remains a significant global health burden despite availability of current antiviral treatments. With increasing drug resistance against available therapeutics, there is an urgent need for additional strategies to treat HIV. Technical Details: Researchers at Johns Hopkins University have identified novel candidates for HIV...
Published: 5/9/2024   |   Inventor(s): David Thomas, Ashwin Balagopal, Ramy El-Diwany, Robert Siliciano, Joel Blankson, Stuart Ray, Michael Chattergoon, Justin Bailey
Keywords(s): Biomarker, Disease Indication, HIV, HIV/AIDS, Infectious Diseases, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics, Viral Infections
Category(s): Clinical and Disease Specializations, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Infectious Diseases > Viral Infections
Compositions and Biomarkers for Human Cancer and Methods of Use
Novel biomarkers for the detection and prognosis of several cancersJHU REF: C12506  Invention novelty: This invention has discovered high frequency mutations in the telomerase reverse transcriptase (TERT) promoter of certain cancers.   Value Proposition: Early detection is usually critical for the successful treatment of cancer, therefore there is...
Published: 5/9/2024   |   Inventor(s): Bert Vogelstein, Kenneth Kinzler, Nickolas Papadopoulos, Chetan Bettegowda, Yuchen Jiao, Darell Bigner, Hai Yan, Zachary Reitman, Patrick Killela
Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities
Hepatic Kisspeptin Secretion Impairs Insulin Secretion from Pancreatic Bets Cell. Kisspeptin Receptor GPR54 Antagonist for Treatment of Prediabetes and Diabetes Mellitus in Humans.
Unmet NeedGlucagon and insulin work together to keep blood glucose levels balanced. Glucagon stimulates the liver to secrete glucose while insulin suppresses glucose release. If the body does not regulate glucose levels properly, Type 2 diabetes mellitus (T2DM) will develop. Type 2 diabetes mellitus is a world-wide epidemic, projected to affect 1/3...
Published: 5/9/2024   |   Inventor(s): Woo-Jin Song, Prosenjit Mondal, Mehboob Hussain
Keywords(s): Biomarker, Diabetes, Disease Indication, Mechanism-of-action Biomarker, Metabolic Disorders, Therapeutic Matter, Therapeutics, Type 2 Diabetes, Type II Diabetes
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Diabetes, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes
Olfr90 and Fungal Volatiles
Unmet NeedIncreasingly, invasive mold infections have been recognized in people who are immune compromised by genetic conditions, aging, other infections (e.g. HIV) and modern medicine (e.g. transplantation). Moreover, increasing evidence points to the role of these organisms as causes of environmental toxicities and industrial spoilage. An over-abundance...
Published: 5/9/2024   |   Inventor(s): Kieren Marr, Jennifer Pluznick, Victoria Halperin-Kuhns
Keywords(s): Assay, Biomarker, Clinical Diagnostics, Disease Indication, Environmental Sensing, Fungal Infections, Imaging and Sensing Systems, In Vitro Diagnostics, Mechanism-of-action Biomarker, Sensing Modality, Therapeutic Matter, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Fungal Infections, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities
Semaphorin 3D and Plexin D1 as New Therapeutic Targets for Pancreatic Cancer Treatment
Unmet Need: Most patients with pancreatic ductal adenocarcinoma (PDA) present with metastatic disease at the time of diagnosis or will recur with metastases after surgical treatment. Technology Overview: Semaphorin-plexin signaling mediates the migration of neuronal axons during development and of blood vessels during angiogenesis. The expression of...
Published: 5/9/2024   |   Inventor(s): Lei Zheng
Keywords(s): Biomarker, Cancer Cells, Cancers, Cell Model, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Mechanism-of-action Biomarker, Pancreatic Cancer, Target, Therapeutic Matter, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities
Identification of LAG3 as the α-synuclein Neuronal Transmission Receptor
Unmet Need: Parkinson’s disease (PD) is the second most common neurodegenerative disorder and leads to slowness of movement, tremor, rigidity, and, in the later stages of PD, cognitive impairment. Pathologically, PD is characterized by the accumulation of α-synuclein in Lewy bodies and neurites. Emerging evidence indicates that the pathogenesis of Parkinson's...
Published: 5/9/2024   |   Inventor(s): Ted Dawson, Valina Dawson, Han Seok Ko, Xiaobo Mao, Dario Vignali, Creg Workman
Keywords(s): Biomarker, CNS and Neurological Disorders, Disease Indication, Mechanism-of-action Biomarker, Parkinson's Disease, Therapeutic Matter, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology > Parkinson's Disease, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities
Activating Mutations in GNAQ Sensitive to Antibiotic; Novel Molecular Pathway and Treatment Target for Capillary Malformations and Related Syndromes
An unexpected observation while working on developing cell models for these vascular abnormalities generated the following idea: Cells with the capillary malformation/ Sturge-Weber syndrome mutation may be more sensitive to an antibiotic than normal cells. This suggests a particular cell molecular pathway may be signaling abnormally in these cells...
Published: 5/9/2024   |   Inventor(s): Anne Comi, Jonathan Pevsner, Zhenhua Huang, Douglas Marchuk
Keywords(s): Biomarker, Disease Indication, Genetic Disorders, Mechanism-of-action Biomarker, Skin Disorders, Sturge-Weber Syndrome, Sturge-Weber Syndrome (SWS), Target, Therapeutic Matter, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology > Sturge-Weber Syndrome, Clinical and Disease Specializations > Genetic Diseases, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Dermatology, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities
1 2 3 4 5 6 
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum